Assembly Biosciences Inc (ASMB) Q2 2019 10-Q Quarterly Earnings

Short answer

Assembly Biosciences Inc (ASMB) filed its Q2 2019 10-Q quarterly report on Aug 5, 2019 for the quarter ended Jun 30, 2019.

AI summary of MD&A and risk factor updates

Collaboration revenue $3.1M, down from $3.2M YoY
Net loss $45.6M, up from $43.1M YoY
R&D expense $18.7M, up from $17.9M YoY, driven by Microbiome spending
Operating cash use $44.9M vs $31.5M YoY
Cash, equivalents and marketable securities expected to fund operations at least twelve months, with additional capital likely needed

No newly triggered risk identified, the filing presents standard carried-forward risks without comparing changes to the prior 10-K
Clinical development risk: early-stage HBV and Microbiome candidates may fail to demonstrate safety or efficacy
Regulatory risk: GDPR noncompliance could incur penalties up to €20 million or 4% of worldwide revenue
Operational risk: reliance on third-party manufacturers could delay clinical supplies or increase costs
Financial risk: accumulated deficit approximately $387.3 million as of June 30, 2019, with funding needed for future operations

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Compare quarters, check guidance or see what insiders and funds did around the report.